SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Biology

Cancer Oncology

Medicine

Paleontology

Internal Medicine

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.tps8657